Myriad Genetics to Participate in BofA Securities Healthcare Conference
May 02, 2023 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, May 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will be participating in the upcoming...
Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
April 26, 2023 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, April 26, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on...
77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
April 19, 2023 07:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, April 19, 2023 (GLOBE NEWSWIRE) -- From restricted or binge eating to excessive gambling to extreme social media use, 77% of Americans surveyed say they have used at least one...
Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification
April 18, 2023 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, April 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, a service of...
Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program
April 12, 2023 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, April 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and SimonMed® Imaging, one of the largest independent...
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
March 02, 2023 09:15 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, March 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetic, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA...
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
March 01, 2023 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the first evidence-based...
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
February 28, 2023 16:05 ET
|
Myriad Genetics, Inc.
Highlights: Fourth quarter testing volumes grew 26% year-over-year, and 11% year-over-year excluding the contribution from the recent acquisition of Gateway Genomics and its SneakPeek® Early Gender...
Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023
February 22, 2023 07:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth-quarter earnings conference call on...
Myriad Genetics to Participate in Upcoming Healthcare Conferences
February 09, 2023 07:15 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate at the...